Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 3/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313525 | 0.86 | ALDH1A1 (0.34) | LMNASMN1; SMN2MAPTGAAALOX15 | |
| SCHEMBL6314899 | 0.82 | LMNA (0.38) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL6313477 | 0.81 | KDM4E (0.49) | LMNAKDM4EMAPTTSHRHPGD | |
| SCHEMBL6319276 | 0.80 | CACNA1F (0.52) | CACNA1FCACNA1DCACNA1SCACNA1CSMN1; SMN2 | |
| SCHEMBL6312968 | 0.77 | ALDH1A1 (0.52) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL6318792 | 0.77 | ALDH1A1 (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL6321647 | 0.76 | CACNA1C (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL6313485 | 0.74 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 | |
| SCHEMBL6314714 | 0.74 | CACNA1C (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL6312995 | 0.74 | SMN1; SMN2 (0.39) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809102-B2 | FOR THERAPY OF PROLIFERATIVE DISEASES, SUCH AS CANCER; TO INTERRUPT MITOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-26 | — | — | US | claimed |
| EP-1373221-A4 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1373221-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | claimed |
| WO-2002079149-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6809102-B2 | FOR THERAPY OF PROLIFERATIVE DISEASES, SUCH AS CANCER; TO INTERRUPT MITOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-26 | — | — | US | disclosed |
| EP-1373221-A4 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373223-A4 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373221-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1373223-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002079169-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002079149-A2 | NOVEL CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | CACNA1F 3082/4885CACNA1D 3435/4885CACNA1S 3122/4885 |
| US-20030008888-A1 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | CACNA1F 3260/4885CACNA1D 3438/4885CACNA1S 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.